Cheng J, Sun M, Dong X, Yang Y, Qin X, Zhou X
BMC Cancer. 2025; 25(1):161.
PMID: 39875895
PMC: 11773968.
DOI: 10.1186/s12885-025-13560-y.
Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A
BMC Med. 2024; 22(1):578.
PMID: 39639257
PMC: 11622503.
DOI: 10.1186/s12916-024-03775-4.
Cortes Ballen A, Amosu M, Ravinder S, Chan J, Derin E, Slika H
Cells. 2024; 13(18.
PMID: 39329757
PMC: 11430559.
DOI: 10.3390/cells13181574.
Erb H, Polishchuk N, Stasyk O, Kahya U, Weigel M, Dubrovska A
Cancers (Basel). 2024; 16(16).
PMID: 39199642
PMC: 11352381.
DOI: 10.3390/cancers16162871.
Kohara Y, Yasuda S, Nagai M, Nakamura K, Matsuo Y, Terai T
Ann Surg Oncol. 2024; 31(12):7713-7721.
PMID: 39107610
DOI: 10.1245/s10434-024-15985-4.
Molecular and cellular mechanisms of chemoresistance in paediatric pre-B cell acute lymphoblastic leukaemia.
Lill C, Fitter S, Zannettino A, Vandyke K, Noll J
Cancer Metastasis Rev. 2024; 43(4):1385-1399.
PMID: 39102101
PMC: 11554931.
DOI: 10.1007/s10555-024-10203-9.
Targeting the glutamine-arginine-proline metabolism axis in cancer.
Wang D, Duan J, Guo Y, Chen J, Chen T, Wang J
J Enzyme Inhib Med Chem. 2024; 39(1):2367129.
PMID: 39051546
PMC: 11275534.
DOI: 10.1080/14756366.2024.2367129.
Glutathione‑degrading enzymes in the complex landscape of tumors (Review).
Zhang T, Yao C, Zhou X, Liu S, Qi L, Zhu S
Int J Oncol. 2024; 65(1).
PMID: 38847236
PMC: 11173371.
DOI: 10.3892/ijo.2024.5660.
Enzymatic depletion of circulating glutamine is immunosuppressive in cancers.
Kumar M, Leekha A, Nandy S, Kulkarni R, Martinez-Paniagua M, Sefat K
iScience. 2024; 27(6):109817.
PMID: 38770139
PMC: 11103382.
DOI: 10.1016/j.isci.2024.109817.
Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment.
Fan Y, Xue H, Li Z, Huo M, Gao H, Guan X
Front Pharmacol. 2024; 15:1345522.
PMID: 38510646
PMC: 10952006.
DOI: 10.3389/fphar.2024.1345522.
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle.
Wang B, Pei J, Xu S, Liu J, Yu J
J Exp Clin Cancer Res. 2024; 43(1):74.
PMID: 38459595
PMC: 10921613.
DOI: 10.1186/s13046-024-02994-0.
characterization of nonribosomal peptide synthetase-dependent -(2-hydrazineylideneacetyl)serine synthesis indicates a stepwise oxidation strategy to generate the α-diazo ester moiety of azaserine.
Shikai Y, Kawai S, Katsuyama Y, Ohnishi Y
Chem Sci. 2023; 14(33):8766-8776.
PMID: 37621439
PMC: 10445470.
DOI: 10.1039/d3sc01906c.
Metabolites and Immune Response in Tumor Microenvironments.
Cortellino S, Longo V
Cancers (Basel). 2023; 15(15).
PMID: 37568713
PMC: 10417674.
DOI: 10.3390/cancers15153898.
Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.
Minet N, Boschat A, Lane R, Laughton D, Beer P, Asnagli H
Life Sci Alliance. 2023; 6(9).
PMID: 37348953
PMC: 10288033.
DOI: 10.26508/lsa.202302066.
Differential Effects of Glutamine Inhibition Strategies on Antitumor CD8 T Cells.
Madden M, Ye X, Chi C, Fisher E, Wolf M, Needle G
J Immunol. 2023; 211(4):563-575.
PMID: 37341499
PMC: 10526752.
DOI: 10.4049/jimmunol.2200715.
Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.
Song J, Pan C, Li J, Bai R, Zeng Z, Han Y
ACS Med Chem Lett. 2023; 14(1):11-17.
PMID: 36655131
PMC: 9841584.
DOI: 10.1021/acsmedchemlett.2c00302.
Effects of metabolic cancer therapy on tumor microenvironment.
Hyrossova P, Milosevic M, Skoda J, Vachtenheim Jr J, Rohlena J, Rohlenova K
Front Oncol. 2022; 12:1046630.
PMID: 36582801
PMC: 9793001.
DOI: 10.3389/fonc.2022.1046630.
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R, Lemberg K, Tenora L, Arwood M, Pal A, Alt J
Sci Adv. 2022; 8(46):eabq5925.
PMID: 36383674
PMC: 9668306.
DOI: 10.1126/sciadv.abq5925.
Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities.
Kovalev I, Zyryanov G, Santra S, Majee A, Varaksin M, Charushin V
Molecules. 2022; 27(19).
PMID: 36234766
PMC: 9573478.
DOI: 10.3390/molecules27196229.
Taming glutathione potentiates metallodrug action.
Nguyen H, Do L
Curr Opin Chem Biol. 2022; 71:102213.
PMID: 36206677
PMC: 9759795.
DOI: 10.1016/j.cbpa.2022.102213.